$STX

Morris John Christopher sold $3.4M of STX

Morris John Christopher (EVP & CTO) sold 4,038 shares of Seagate Technology Holdings plc (STX) at an average of $847.57 ($835.54–$849.35, $3.42M total) across 4 trades over 2026-08-20 to 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Morris John Christopher
Published Aug 24, 2026, 9:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Neutral
medium confidence
Mentioned
$STX
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

The sale represents a routine liquidity event; no material change to Seagate's fundamentals.

02

Market read

The filing provides a modest update on insider holdings with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or strategic moves not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: filed 2026-08-24

Background

Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$STXNeutralMedium confidence
Context

EVP & CTO Morris John Christopher sold 4,038 shares of Seagate (STX) for $3.42M via a 10b5‑1 plan.

Expected impact

Limited short‑term impact; price likely unchanged.

Evidence & confidence

Sale size ($3.4M) is modest for a large cap; insider is selling under a pre‑arranged plan, suggesting no new negative information.

Market effects

Minimal effect on the data‑storage sector; no broader industry signal.

None; transaction is US‑based and does not affect regional markets.

Low; only relevant to Seagate shareholders.

Counterpoint

If the insider sale signals confidence in the stock, the market could view it as a neutral or even positive sign.

Key entities

  • Seagate Technology Holdings plc

    Global data storage solutions provider.

  • Morris John Christopher

    EVP & CTO of Seagate.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.